Children with Down syndrome (DS) have a greatly increased risk of acute megakaryoblastic leukaemia (AMKL) and acute lymphoblastic leukaemia (ALL). Both DS-AMKL and the related transient myeloproliferative disorder (TMD) have GATA1 mutations as obligatory, early events. To identify mutations contributing to leukaemogenesis in DS-ALL we undertook sequencing of candidate genes including FLT3, RAS, PTPN11, BRAF and JAK2.
Introduction
Children with Down syndrome (DS), characterised by constitutional trisomy 21, have a 50 fold increased risk of developing acute leukaemia in the first few years of life 1, 2 . This comprises the normally extremely rare subtype acute megakaryoblastic leukaemia (AMKL) as well as the common variety (B-cell precursor) of acute lymphoblastic leukaemia (ALL) [2] [3] [4] .
Both DS-AMKL and the transient myeloproliferative disorder (TMD) that often precedes it are consistently associated with acquired mutations in the GATA1 gene 5 . Concordant GATA1 mutations in the blast cells of identical twins with TMD 6 and mutations in the neonatal blood spots of DS newborns 7 indicate that this is an early/prenatal event in DS leukaemogenesis.
Much less is known about the genetic events predisposing to DS-ALL. Candidate genes for activating mutations in DS-ALL include FLT3 and RAS, both mutated in high hyperdiploid ALL (with acquired trisomy 21) 8, 9 , PTPN11 and BRAF, mutated in B-cell precursor ALL 10, 11 . An additional candidate is the JAK2 pseudokinase domain mutation JAK2ΔIREED, reported in a single case of DS-ALL 12 . A different JAK2 pseudokinase domain mutation, JAK2V617F, is frequently found in the myeloproliferative disorders (MPD) and believed to be an initiating event [13] [14] [15] . Submicroscopic deletions involving genes linked functionally to deregulation of cell cycling or B cell differentiation have also been implicated in the molecular pathogenesis of ALL [16] [17] [18] [19] . In this study we undertook both sequencing of candidate genes and high resolution SNP array analysis to identify genetic events associated with ALL in DS.
Materials and Methods

Patients
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Patients' samples (Table 1, S1) were obtained with informed consent in accordance with the Declaration of Helsinki and the study was carried out with ethical review committee approval from all participating institutions. DNA was extracted from archival (frozen cell or cytogenetic fixed pellet) leukaemic samples.
Sequencing
Primers were designed to amplify the following candidate genes: FLT3 ITD, FLT3 kinase domain, KIT kinase domain, PTPN11, BRAF, NRAS, and KRAS (Table S2A) . of the JAK2 gene were PCR-amplified and sequenced using previously described primers 13 .
All samples found to be mutated were PCR-amplified and sequenced in a second, independent experiment. Pyrosequencing was carried out in accordance to manufacturer's instructions (Biotage AB, Upsala, Sweden) using the primers shown in Table S2B .
Ba/F3 proliferation assay
MSCV-neo-IRES-GFP murine wild type JAK2 and JAK2R683G constructs were transfected into GP2 packaging cells to produce retroviruses as previously described 13 . Ba/F3 cells were co-transduced with MSCV-puro-TpoR retrovirus and selected in media containing 2 mg/ml G418 and 0.5μg/ml puromycin, and further cultured in the presence or absence of IL-3 with or without 10μM tyrosine kinase inhibitor AG490 (Invitrogen).
SNP arrays
Leukaemic DNA from the patient's bone marrow at presentation of ALL and remission DNA (as germline control) was genotyped with Affymetrix Human GeneChip Mapping 250K Nsp1
and Sty1 arrays as previously described 19, 20 . Array hybridization data were analyzed for loss of heterozygosity and signal intensity using the GOLF software program (for more details see
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Results and Discussion
Sequencing of selected exons of the FLT3, KIT, PTPN11, BRAF, NRAS and KRAS genes in a series of ten DS-ALL cases did not identify any mutations (Table S1 ). Sequencing of JAK2 exon 14 in 42 cases of DS-ALL identified a point mutation at the conserved arginine (R683) affected by the IREED deletion 12 in 12/42 (28%) cases. Ten of these were an identical arginine to glycine (JAK2R683G) and two an arginine to serine (JAK2R683S) substitution.
The mutation was acquired in the leukaemic blasts ( Figure 1A ). proteins, whereas the wild type JAK2 did not ( Figure 1B ). The R683G mutation allowed IL-3 dependent Ba/F3 cells to survive and proliferate in the absence of IL-3 and this effect was abrogated in the presence of the JAK2 kinase inhibitor AG490 ( Figure 1C ). These data parallel the impact of the JAK2V617F mutation in MPD [13] [14] [15] For
Cytogenetic analyses of our cases of DS-ALL, with or without the JAK2R683 mutation, indicated the presence of additional chromosomal lesions (Table S1 ). In common with other reports 21 , our series had a lower than usual incidence of common fusion genes (e.g ETV6-RUNX1) and high hyperdiploidy. There do not appear to be any cytogenetic features that distinguish the DS-ALL cases with the JAK2R683 mutation from those without.
High resolution SNP array analysis of nine DS-ALL cases identified between 1 and 13 regions of loss or gain per case (Table S3) . Small focal deletions, often involving a single gene, were identified in many cases. The most common deletion (4/9 cases) involved the ETV6 gene ( Figure S1 ). Focal deletions of other genes implicated in ALL pathogenesis included the CDKN2A (3/9 cases) PAX5 (2/9 cases) BTLA, EBF1, and RB1 genes (one case each). The pattern and number of microdeletions in this series, in particular the high incidence of ETV6 deletions, more closely resembled ETV6-RUNX1 positive ALL than other subgroups of ALL 16 . There were no microdeletions unique to the JAK2 mutated cases.
Our data indicates that multiple genetic events including cytogenetically detectable chromosome aneuploidy, submicroscopic deletions of genes including ETV6, CDKN2A and PAX5, as well as activating JAK2 mutations can occur, collectively complementing constitutional trisomy 21 in DS-ALL. The functional studies of the JAK2R683G mutation indicate that this is most likely a 'driver' mutation 22 in a subset of patients with DS-ALL but the sequence of acquired genetic events, in utero and post-natally, remains to be established.
In one case in the present study (Patient 9, Table S1), the JAK2R683G mutation was acquired only at relapse. In another (Patient 10, Table S1 ) the mutation appeared to be subclonal, as pyrosequencing found 32% mutant compared with 99% blasts. These data indicate that the mutation can, in some cases, be a late or secondary event.
The absence (or rarity) of JAK2 mutations in non-DS B-cell precursor ALL, including cases with acquired trisomy 21, and the high risk of ALL in DS syndrome indicates that 
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